Starboard Value · activist-deck
Starboard Value | Activist Presentation Deck | 74 slides
74 pages · 3 arc beats · 3 loops
Starboard Value | Activist Presentation Deck | 74 slides
Starboard Value · 2024-10 arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
151015202530354045505560657074
Deck intelligence map
3 coverage by narrative range · generated from this deck JSON
Narrative range 34 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem (Identify pain) 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits — 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides — 0/1 slides
Agitate (Make it worse) 20 slides 100% 20/20 slides 100% 20/20 slides · 106 hits — 0/20 slides
— 0/20 slides
80% 16/20 slides 100% 20/20 slides 45% 9/20 slides Solution (Provide relief) 13 slides 100% 13/13 slides 100% 13/13 slides · 59 hits — 0/13 slides
23.1% 3/13 slides 92.3% 12/13 slides 100% 13/13 slides 38.5% 5/13 slides Slide inventory
74 every slide · same image gating as the playbook
03
The slide uses a segmentation framework to highlight the company's market presence and societal impact.summarize
05
Uses a dual-axis chart to visually suggest causality between vaccine rollout and death rate reduction.illustrate_case
06
The slide uses a visual callout to emphasize the $40bn incremental FCF figure.quantify_opportunity
07
The chart uses a red vertical arrow to quantify the 132-point gap between the market and Pfizer.compare_peers
08
The chart uses a custom bridge structure to calculate total value lost by adding market cap decline and COVID benefit.show_valuation_bridge
09
The chart highlights LLY and NVO as GLP-1 participants; PFE is highlighted in a different color.compare_peers
10
Uses a funnel-like visual structure to connect specific operational issues to broader financial outcomes.diagnose_problem
Open slide detailBeat · Problem (Identify pain)
12
The chart uses a dashed box to highlight PFE and a dashed red line to indicate the peer median of 46 drugs.compare_peers
13
Uses authority bias to validate the activist's thesis that the company was already well-positioned for growth.cite_precedent
14
The slide uses a series of quotes to establish a narrative of management over-promising on pipeline quality.expose_contradiction
15
The slide uses a quote to highlight a specific management commitment, likely to be contrasted with later performance.expose_contradiction
16
The slide is used by Starboard Value to contrast Pfizer's historical R&D projections with current performance.expose_contradiction
17
The slide uses a table to track 15 specific drug programs, noting their therapeutic area, next steps, and timing, with symbols indicating status (check for apprexpose_contradiction
18
The slide uses a table to highlight specific programs that had already achieved approvals or failed (negative pivotal data) to challenge the company's narrativeexpose_contradiction
19
The slide uses a table from a third-party source (Pfizer) to build an activist argument about management performance.expose_contradiction
20
The slide uses a dashed line to represent the blockbuster threshold and includes a callout box explaining the donation of royalties.expose_contradiction
21
Uses a screenshot of a news article as evidence of failure.expose_contradiction
Open slide detailBeat · Agitate (Make it worse)
22
Uses a red arrow annotation to emphasize the gap between projected 2030 sales and the blockbuster threshold.diagnose_problem
Open slide detailBeat · Agitate (Make it worse)
23
The slide uses a visual gap analysis to highlight the shortfall against a market benchmark.preempt_rebuttal
Open slide detailBeat · Agitate (Make it worse)
24
The slide uses a highlighted excerpt from a third-party report to undermine the company's R&D track record.expose_contradiction
Open slide detailBeat · Agitate (Make it worse)
25
The slide uses a screenshot of a press release to validate the claim of continued product success.cite_precedent
Open slide detailBeat · Agitate (Make it worse)
26
The slide uses analyst quotes to build a case for competitive pressure on Pfizer's core product.cite_precedent
Open slide detailBeat · Agitate (Make it worse)
27
The slide uses a direct quote from a press release to highlight a clinical trial failure.expose_contradiction
Open slide detailBeat · Agitate (Make it worse)
28
The slide uses a primary source excerpt to establish the clinical efficacy and subsequent commercial success of the drug.cite_precedent
Open slide detailBeat · Agitate (Make it worse)
29
The slide uses a screenshot of a news article as evidence.cite_precedent
Open slide detailBeat · Agitate (Make it worse)
30
The slide highlights a contradiction between the CEO's stated focus on innovation and the market's focus on shareholder return.expose_contradiction
Open slide detailBeat · Agitate (Make it worse)
31
The slide uses a 'before-after' framing by contrasting past management promises with current performance.expose_contradiction
32
Uses highlighted text to draw attention to specific claims within the quotes.expose_contradiction
33
The slide highlights the skepticism of Wall Street analysts regarding management's projections.expose_contradiction
34
Uses a 'villain critique' style to undermine management's R&D track record.expose_contradiction
35
The chart highlights the massive gap between company optimism and market reality.expose_contradiction
36
The chart highlights the divergence in GLP-1 success between the two peers and the implied laggard (Pfizer).compare_peers
38
The chart highlights Pfizer's underperformance relative to peers, including a specific callout for 'PFE Excl. COVID'.compare_peers
39
The chart uses a 'broken axis' visual style for the top two bars (LLY, NVO) to accommodate their significantly higher growth rates.compare_peers
40
The chart uses a broken axis for the top two performers (NVO, LLY) to accommodate the scale.compare_peers
42
The slide highlights the scale of capital allocation into M&A, framing it as a potential misuse of COVID-19 windfall cash.diagnose_problem
Open slide detailLoop · Cost Of Inaction
43
The slide uses a visual comparison to contrast the $70B spend against the $20.5B revenue target, implying poor capital allocation.expose_contradiction
Open slide detailLoop · Cost Of Inaction
44
The chart uses a red bar to emphasize the outlier status of the 'PFE Consolidated Deals (Mgmt)' metric.compare_peers
Open slide detailLoop · Cost Of Inaction
45
The slide uses a stacked bar chart to contrast company expectations ($20.5bn) against sell-side consensus ($13.3bn).expose_gap
Open slide detailLoop · Cost Of Inaction
46
The chart highlights the discrepancy between management's valuation assumptions and consensus expectations.show_valuation_bridge
Open slide detailLoop · Cost Of Inaction
47
The slide uses a combination of a table and a bar chart to illustrate the delta in valuation.show_valuation_bridge
Open slide detailLoop · Cost Of Inaction
48
Uses a press release excerpt with annotations to build a valuation argument.expose_contradiction
Open slide detailLoop · Cost Of Inaction
49
The slide uses a direct quote/screenshot from a press release to undermine the value of a previous acquisition (GBT).expose_contradiction
Open slide detailLoop · Cost Of Inaction
50
The slide uses analyst quotes to frame Pfizer's acquisition strategy as flawed.expose_contradiction
Open slide detailLoop · Cost Of Inaction
52
Uses checkmarks and X marks to visualize performance; highlights 2021-2022 as a 'COVID Benefit' period.expose_contradiction
53
The chart uses color coding (red bars) to emphasize Pfizer's lower consistency compared to the peer group.compare_peers
54
Uses red 'X' icons to visually emphasize the failure to meet expectations.expose_contradiction
55
The slide uses a waterfall-like annotation to explain the drop in sales from 2022 to 2023.expose_contradiction
56
The slide uses a chart to highlight management's optimistic outlook, likely to contrast with actual performance or market skepticism.expose_contradiction
57
The slide uses a red color for the actuals bar and the annotation to emphasize the negative performance.expose_contradiction
58
Uses red color coding to emphasize the negative performance and missed guidance.expose_contradiction
59
Uses a red-blue contrast to emphasize the negative gap between market expectations and company guidance.expose_contradiction
60
The slide uses bolded and underlined text within quotes to highlight key negative sentiment.expose_contradiction
62
The slide uses highlighting to emphasize key phrases in the CEO's quote regarding TSR and innovation.cite_precedent
Open slide detailBeat · Solution (Provide relief)
63
The chart uses a red vertical arrow to explicitly quantify the 132-point gap between the S&P 500 and Pfizer.compare_peers
Open slide detailBeat · Solution (Provide relief)
64
The slide uses a competitor's own slide to demonstrate failure to meet stated objectives.expose_contradiction
Open slide detailBeat · Solution (Provide relief)
66
The chart uses a broken axis for the top two performers (NVO, LLY) to accommodate the scale.compare_peers
67
Uses a simple division framework to highlight capital allocation inefficiency.analyze_data
68
The slide uses a waterfall chart to critique capital allocation efficiency.analyze_data
69
Uses a 'bridge' style calculation to derive an incremental revenue requirement.quantify_opportunity
70
The chart uses a standard waterfall bridge format to show the impact of LOEs and growth on 2030 revenue projections.show_valuation_bridge
71
Uses a simple causal chain diagram to link the target return to financial outcomes.propose_solution
Open slide detailBeat · Solution (Provide relief)
73
The chart includes a specific callout for 'PFE (Median R&D Efficiency)' at the end, suggesting a comparison of valuation vs. efficiency.compare_peers
Open slide detailBeat · Solution (Provide relief)